|
1
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitry E, Bouvier AM, Esteve J and Faivre
J: Improvement in colorectal cancer survival: A population-based
study. Eur J Cancer. 41:2297–2303. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rougier P and Mitry E: Epidemiology,
treatment and chemoprevention in colorectal cancer. Ann Oncol.
14:(Suppl 2). ii3–ii5. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Holt PR, Kozuch P and Mewar S: Colon
cancer and the elderly: From screening to treatment in management
of GI disease in the elderly. Best Pract Res Clin Gastroenterol.
23:889–907. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Extermann M, Overcash J, Lyman GH, Parr J
and Balducci L: Comorbidity and functional status are independent
in older cancer patients. J Clin Oncol. 16:1582–1587.
1998.PubMed/NCBI
|
|
7
|
Meyerhardt JA, Catalano PJ, Haller DG,
Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of
diabetes mellitus on outcomes in patients with colon cancer. J Clin
Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY,
Liu CY, Chen CZ and Liu YW: Angiogenesis inhibitor bevacizumab
increases the risk of ischemic heart disease associated with
chemotherapy: A meta-analysis. PLoS One. 8:e667212013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polk A, Vistisen K, VaageNilsen M and
Nielsen DL: A systematic review of the pathophysiology of
5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol.
15:472014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saliba D, Elliott M, Rubenstein LZ,
Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG,
Sloss EM and Wenger NS: The Vulnerable Elders Survey: A tool for
identifying vulnerable older people in the community. J Am Geriatr
Soc. 49:1691–1699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fried LP, Tangen CM, Walston J, Newman AB,
Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, et al:
Cardiovascular Health Study Collaborative Research Group: Frailty
in older adults: Evidence for a phenotype. J Gerontol A Biol Sci
Med Sci. 56:M146–M156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lan YT, Yang SH, Chang SC, Liang WY, Li
AF, Wang HS, Jiang JK, Chen WS, Lin TC and Lin JK: Analysis of the
seventh edition of American Joint Committee on colon cancer
staging. Int J Colorectal Dis. 27:657–663. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grothey A and Goldberg RM: A review of
oxaliplatin and its clinical use in colorectal cancer. Expert Opin
Pharmacother. 5:2159–2170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohelnikova-Duchonova B, Melichar B and
Soucek P: FOLFOX/FOLFIRI pharmacogenetics: The call for a
personalized approach in colorectal cancer therapy. World J
Gastroenterol. 20:10316–10330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edwards MS, Chadda SD, Zhao Z, Barber BL
and Sykes DP: A systematic review of treatment guidelines for
metastatic colorectal cancer. Colorectal Dis. 14:e31–e47. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Extermann M, Albrand G, Chen H, Zanetta S,
Schonwetter R, Zulian GB, Cantor A and Droz JP: Are older French
patients as willing as older American patients to undertake
chemotherapy? J Clin Oncol. 21:3214–3219. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balducci L and Extermann M: Management of
cancer in the older person: A practical approach. Oncologist.
5:224–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Wang FH, Bai L and Xu RH: Role of
capecitabine in treating metastatic colorectal cancer in Chinese
patients. Onco Targets Ther. 7:501–511. 2014.PubMed/NCBI
|
|
20
|
Chu E, Eng C, Abbruzzese J, et al:
Efficacy and safety of capecitabine for colorectal cancer. Am J
Oncol Rev. 2:(Suppl 3). 1–28. 2003.
|
|
21
|
Escudero P, Verge V, Feliu J, SanzLacalle
J, Lopez R, Gomez MJ, Aparicio A, Yubero A, Lorenzo A and
Gonzalez-Baron M: A study of capecitabine in elderly patients as
first line treatment in advanced or metastatic colorectal cancer.
Proc Am Soc Clin Oncol. 22:abstract 3114. 2003.
|
|
22
|
Cripps MC, Vincent M, Jonker D, Kerr I,
Dingle B, Martin LA, Mathews J, Biagi J, Knight G and Lam W: Dose
reduced first line capecitabine monotherapy in older and less fit
patients with advanced colorectal cancer (ACRC). J Clin Oncol.
23:35772005.PubMed/NCBI
|
|
23
|
Jung YH, Lee WJ, Byeon JH, Lee IK, Han CW
and Woo IS: Metronomic chemotherapy with capecitabine for
metastatic colorectal cancer in very elderly patients. Korean J
Intern Med. Mar 10–2016.(Epub ahead of print). View Article : Google Scholar
|
|
24
|
Stein A, Quidde J, Schröder JK, Göhler T,
Tschechne B, Valdix AR, Höffkes HG, Schirrmacher-Memmel S,
Wohlfarth T, Hinke A, Engelen A and Arnold D: Capecitabine in the
routine first-line treatment of elderly patients with advanced
colorectal cancer - results from a non-interventional observation
study. BMC Cancer. 16:822016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feliu J, Escudero P, Llosa F, Bolaños M,
Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gómez L,
Casado E, Gómez-Reina MJ and González-Baron M: Capecitabine as
first-line treatment for patients older than 70 years with
metastatic colorectal cancer: An oncopaz cooperative group study. J
Clin Oncol. 23:3104–3111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohhara Y, Fukuda N, Takeuchi S, Honma R,
Shimizu Y, Kinoshita I and DosakaAkita H: Role of targeted therapy
in metastatic colorectal cancer. World J Gastrointest Oncol.
8:642–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Begg CB and Carbone PP: Clinical trials
and drug toxicity in the elderly: The experience of the Eastern
Cooperative Oncology Group. Cancer. 52:1986–1992. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cascinu S, Del Ferro E and Catalano G:
Toxicity and therapeutic response to chemotherapy in patients aged
70 years or older with advanced cancer. Am J Clin Oncol.
19:371–374. 1996. View Article : Google Scholar : PubMed/NCBI
|
